The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.The company is set to capture 50% ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Eli Lilly (LLY-0.12%) and Novo Nordisk are the two undisputed frontrunners, but many other drugmakers are looking to challenge the status quo. Novo Nordisk's Wegovy, first approved in the U.S. in ...

Eli Lilly on Thursday launched a website to enable people to directly ... on the back of extraordinary demand seen over the last year for powerful weight-loss drugs such as Novo Nordisk’s Wegovy.

business Health Care. Eli Lilly’s new weight loss drug could drive down prices of Wegovy and Ozempic The Danish drugmaker’s Zepbound will undercut its rivals’ pricing by 21% but still cost ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their insurance. Novo Nordisk is now discounting Wegovy for cash customers too.

Eli Lilly weight loss drug beat Wegovy in a head-to-head clinical trial — 20.2% body weight loss on Zepbound compared to 13.7% on Novo Nordisk obesity drug. Skip to Main Content.

Eli Lilly’s experimental pill for weight loss helped people lose an average of 15% of their body weight after 36 weeks on the highest dose in a midstage trial, rivaling what’s seen with ...